HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.

Abstract
The bioreductive anticancer prodrug CI-1010 ((2R)-1-[(2-bromoethyl)amino]-3-(2-nitro-1H-imidazol-1-yl)-2-propanol hydrobromide) is an alkylating nitroimidazole which shows selective toxicity against hypoxic cells in murine tumors, but causes extensive apoptosis in the outer retina in rodents and monkeys. This irreversible retinal toxicity has terminated preclinical development of CI-1010. We have investigated whether such toxicity is due to physiological hypoxia in the retina, and whether it is a general feature of hypoxia-selective bioreductive drugs. Retinal damage was quantified by morphometric analysis of histological sections following treatment of female C57Bl6 mice. Both CI-1010 and tirapazamine (TPZ, 1,2,4-benzotriazin-3-amine 1,4-dioxide), a bioreductive drug in Phase III clinical trial, caused a time and dose-dependent loss of photoreceptor cells of the outer retina following administration of single intraperitoneal doses. The lesion caused by TPZ was qualitatively similar to that with CI-1010, but was less severe at equivalent fractions of the maximum tolerated dose (as defined by lethality). With both bioreductive drugs, lesion severity was increased if animals breathed 10% O(2) for 3 h after drug administration, while breathing 95% O(2)/5% CO(2) was protective. Other hypoxia-selective bioreductive drugs tested (the quinone porfiromycin, the anthraquinone N-oxide AQ4N and the nitrogen mustard prodrugs SN 23816 and SN 25341) did not cause retinal damage at their maximum tolerated doses. This study suggests that the retinal toxicity of bioreductive drugs might be avoided by manipulation of tissue hypoxia using 95% O(2)/5% CO(2), although this intervention could suppress antitumor activity. The finding that not all bioreductive drugs cause retinal toxicity suggests this toxicity can be avoided through appropriate drug design.
AuthorsA E Lee, W R Wilson
JournalToxicology and applied pharmacology (Toxicol Appl Pharmacol) Vol. 163 Issue 1 Pg. 50-9 (Feb 15 2000) ISSN: 0041-008X [Print] United States
PMID10662604 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright 2000 Academic Press.
Chemical References
  • Antineoplastic Agents
  • Nitroimidazoles
  • Prodrugs
  • Radiation-Sensitizing Agents
  • Triazines
  • RB 6145
  • Tirapazamine
Topics
  • Animals
  • Antineoplastic Agents (toxicity)
  • Dose-Response Relationship, Drug
  • Female
  • Hypoxia (metabolism, pathology, physiopathology)
  • Light (adverse effects)
  • Mice
  • Mice, Inbred C57BL
  • Nitroimidazoles (toxicity)
  • Oxidation-Reduction (drug effects)
  • Prodrugs (toxicity)
  • Radiation-Sensitizing Agents (toxicity)
  • Retina (drug effects, pathology, physiopathology)
  • Tirapazamine
  • Triazines (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: